Tg Therapeutics (TGTX) Change in Receivables (2021 - 2026)
Tg Therapeutics (TGTX) posted quarterly Change in Receivables of $86.4 million for Q1 2026, up 41.82% year-over-year from $60.9 million in Q1 2025, and up 114.74% quarter-over-quarter from $40.2 million in Q4 2025.
Tg Therapeutics (TGTX) Change in Receivables (2021 - 2026) Analysis & Trends
Tg Therapeutics' Change in Receivables history runs 6 years deep, the most recent figure standing at $86.4 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 41.82% year-over-year to $86.4 million; the TTM figure through Mar 2026 stood at $201.9 million (up 61.36% YoY), while the FY2025 annual figure was $176.4 million, up 125.94% from the prior year.
- Change in Receivables for Q1 2026 stood at $86.4 million, up from $40.2 million in the prior quarter.
- The five-year high for Change in Receivables was $86.4 million in Q1 2026, with the low at -$814000.0 in Q2 2022.
- The 5-year median for Change in Receivables is $16.3 million (2024), against an average of $24.4 million.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables slumped 608.75% in 2022, then surged 24913.64% in 2023.
- Tg Therapeutics' Change in Receivables stood at -$88000.0 in 2022, then jumped by 13478.41% to $11.8 million in 2023, then advanced by 14.31% to $13.5 million in 2024, then surged by 199.03% to $40.2 million in 2025, then soared by 114.74% to $86.4 million in 2026.
- Business Quant data shows TGTX's Change in Receivables at $86.4 million in Q1 2026, $40.2 million in Q4 2025, and $33.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 9.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.52 Mn |
| Jun 30, 2026 | 9.52 Mn |
| Mar 31, 2026 | 86.42 Mn |
| Mar 31, 2026 | 86.42 Mn |
| Dec 31, 2025 | 40.24 Mn |
| Dec 31, 2025 | 40.24 Mn |
| Sep 30, 2025 | 33.87 Mn |
| Sep 30, 2025 | 33.87 Mn |
| Jun 30, 2025 | 41.40 Mn |
| Jun 30, 2025 | 41.40 Mn |
| Mar 31, 2025 | 60.94 Mn |
| Mar 31, 2025 | 60.94 Mn |
| Dec 31, 2024 | 13.46 Mn |
| Dec 31, 2024 | 13.46 Mn |
| Sep 30, 2024 | 32.12 Mn |
| Sep 30, 2024 | 32.12 Mn |
| Jun 30, 2024 | 18.63 Mn |
| Jun 30, 2024 | 18.63 Mn |
| Mar 31, 2024 | 13.89 Mn |
| Mar 31, 2024 | 13.89 Mn |